Pluri Biotech Acquires Global IP Position with China Patent for Immune Cell Expansion

Pluri has been granted a patent by the China National Intellectual Property Administration (CNIPA) for large-scale immune cell expansion and secures global IP.

Pluri Biotech, a leading biotechnology company in mass-scale cell expansion and biofarming has announced that it has been granted a patent by the China National Intellectual Property Administration (CNIPA) for proprietary 3D immune cell expansion and activation technology.

The patent, "System and Methods for Immune Cells Expansion and Activation in Large Scale," adds to Pluri's portfolio of granted intellectual property (IP) worldwide, which already includes patents in the US and other countries like Japan, Korea, Australia, and Israel. The company's plan to seek international cooperation and license deals for immune cell therapy products based on Pluri's automated, large-scale production platform is supported by the enlarged portfolio.

Pluri says the system is cost-efficient and supports difficult quality control. The company’s president and CEO, Yaky Yanay said that the patent protection in China which is considered one of the most dynamic cell therapy markets globally, validates the novelty and scalability and he added that their goal is to offer partners a globally protected manufacturing platform capable of supporting large-scale immune cell production.

Growing clinical usage, increased investment, and expanded manufacturing infrastructure have made China one of the most active marketplaces for CAR-T and advanced cell therapies globally. The patent family includes the large-scale manufacturing of several immune cell types, both unmodified and genetically engineered, across a wide range of therapeutic fields.

Pluri Inc., the parent company of Pluri Biotech, operates in the fields of regenerative medicine, foodtech, agriculture, and aesthetics. In a variety of therapeutic areas, there is an increasing demand for large-scale manufacturing of these different cell types, whether genetically modified or not. Pluri's 3D platform enhances this production by including a novel bioreactor technology that mimics the human lymph node environment. By these means, the platform allows mass production with capabilities to expand billions of immune cells.